Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly

Clinics

Volumn 63, Issue 5, 2008, Pages 589-594

  Crisostomo, Luciola M L ^a   Souza, Carlos A M ^a   Mendes, Carlos M C ^a   Coimbra, Silmara R ^b   Favarato, Desiderio ^b   Da Luz, Protasio L ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aged; C reactive protein; Endothelium ultrasonography; Hydroximetilglutaril CoA reductase inhibitors; Lipid

Indexed keywords

EID: 54349091820     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322008000500004     Document Type: Article

References (33)

1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes III J. Factors of risk in the development of coronary heart disease-six year follow-up experience: the Framingham study. Ann Intern Med. 1961;55:30-50.
2. Gordon T, Kannel WB, Castelli WP. Lipoproteins cardiovascular disease and death: The Framingham Study. Arc Intern Med. 1981;141:1128-31.
3. Ravaglia G, Forti P, Maioli F, Boachi F, Cicognani A, Bernardi M et al. Determinants of functional status in healthy Italian nonagenarians and centenarians: a comprehensive functional assessment by the instruments of geriatric practice. J Am Geriatr Soc. 1997;45:1196-202.
4. Lakatta GE, Levy D: Arterial and cardiac aging: shareholders in cardiovascular disease enterprises: Part II: The aging heart in health: Links to heart disease. Circulation. 2003;107:346-54.
5. Stevens J, Jianwen C, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on association between body-mass index and mortality, N Engl J Med. 1998;338:1-7.
6. Furchgott RF & Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
7. Ludmer PL, Selwyn AP, Shook TL. Paradoxal vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Eng J Med. 1986;315:1046-51.
8. Furchgott RF. The discovery of endothelium-derived relaxing factor and is importance in the identification of nitric oxide. JAMA. 1996;276:1186-8.
9. Ridker PM, Cushman M, Stampfer J, Iracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999,340:115-26.
11. Celemajer DS, Sorensen KE, Spiegelhater DJ, Geogakopoulos JR, Deanfield JE. Aging Is Associated With Endothelial Dysfunction in Healthy Men Years Before the Age-Related Decline in Women. J Am Coll Cardiol. 1994;24:471-6.
12. Yataco AR, Corretti MC, Gardner AW, Womack CJ, Katzel LI. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol. 1999;83:754-8.
13. Dupois J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes - The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial. Circulation. 1999; 99:3227-33.
14. Haelst PL van, Doormaal JJ van, Asselbergs FW, Asselbergs FW, van Roon AM, Veeger NJGM et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholestelolaemia. Clinical Science. 2003;104:627-32.
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charboneau F, Creager MA, et al. Guidelines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery. A Report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-65.
16. Coimbra SR, Lage SH, Brandizzi L, Yoshida V, da Luz PL. The action of red wine and purple grape juice on vascular reactivity is independent of plasma lipids in hipercholesterolemic patients. Braz J Med Res. 2005;38:1339-47.
17. Peterson LH, Jensen RE, Parnell MS. Mechanical Properties of Arteries in Vivo. Circulation Research. 1960; 8:622-39.
18. Learoyd BM and Taylor MG. Alterations with Age in the Viscoelastic Properties of Human Arterial Walls. Circulation Research. 1966;28:278-92.
19. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation. 1983;68:50-8.
20. Schroeder S, Enderle MD, Baumbach A, Ossen R, Herdeg C, Kuettner A, et al. Influence of vessel size, age and body mass index on the flow-mediated dilatation (FMD%) of brachial artery. Int J Cardiol. 2000;76:219-25.
21. Herrington DM, Drum M, Riley WA, Pusser BE, Crouse JR, Burke GL et al. Brachial flow-mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter. J Cardiovasc Risk. 2001;8:319-28.
22. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Eng J Med. 1995;332:488-93.
23. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, et al. Atorvastatin Restore Endothelial Function in Normocholesterolemic Smokers Independent of Changes in Low-Density Lipoprotein. Circulation Research. 2004;95:217-23.
24. Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, et al. Accumulation of chylomicron remnants impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis. 2006;187:116-22.
25. Weverling-Rijnsburger AWE, Blauw GJ, Meinders AE. Effect of atorvastatin on impaired vascular function in healthy old men. J Clin Pharm Ther. 2004;29:157-64.
26. Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The Effects of Atorvastatin(10mg) on Systemic Inflammation in Heart Failure. Am J Cardiol. 2005;96:1699-704.
27. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-Reactive Protein and the 1 - Year Incidence of Coronary Heart Disease in Older Men and Women. Circulation. 2005;112:25-31.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
29. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
30. Shepherd J, Blauw GJ, Murphy MB, Ballen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-30.
31. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis (REVERSAL): A Randomized Controlled Trial. JAMA. 2004;291:1071-80.
32. LaRosa JC, Grundy SM, Waters DD, Shear C, Bater P, Fruchart JC, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease (TNT). N Engl J Med. 2005;352:1425-35.
33. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative Safety of Atorvastatin 80mg Versus 10mg. Derived from Analysis of 49 Completed Trials in 14,236 Patients. Am J Cardiol. 2006;97:61-7.